Teva to pay $512m to settle Provigil class action
This article was originally published in Scrip
Teva has agreed to pay $512m to settle a class-action lawsuit in which direct purchasing firms asserted Cephalon, which the Israeli company acquired in 2011, paid generic competitors in 2008 more than $200m to keep cheaper versions of the narcolepsy and sleep apnea drug Provigil (modafinil) off the US market.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.